Here’s what you should know:
1. People who completed either of the first T3MPO phase III studies were eligible for the safety extension study, T3MPO-3.
2. Tenapanor was well-tolerated among the 240 patients that were studied.
3. Of the 240 patients, 9.2 percent experienced diarrhea, with only 1.7 percent of patients discontinuing the treatment because of diarrhea.
4. Throughout all the clinical trials, overall discontinuation rate was only 2.1 percent.
5. Ardelyx plans to submit positive results from the first two T3MPO trials, along with extensive safety data, to the FDA in the second half of 2018 for approval.
More articles on gastroenterology:
GI leader to know: Dr. Elisa Faybush of Arizona Digestive Health
Allergan, Karl Storz Endoscopy & more — 4 GI company key notes
Low-dose polyethylene glycol-based bowel preparation solution acceptable — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.